"Two remedial measures agreed to by ESI could particularly impact pharmaceutical manufacturers: [1] ESI's commitment not to discriminate between high and low list price versions of the same drug, and [2] delinking administrative fees paid by manufacturers from the list price.... [It] is unclear how ESI and the other PBMs will negotiate rebates for high and low list price drugs going forward."  MORE >>